Cardinal Health is in a sustained uptrend, with the stock price up 47.5% over the past year, significantly outperforming the S&P 500's 19.1% gain. The current price of $238.94 sits at 99.2% of its 52-week range (low $137.75, high $240.93), indicating the stock is trading near its highs and reflecting strong bullish momentum. This positioning near the top of the range suggests the market is pricing in continued positive fundamentals, though it also raises the risk of a pullback if catalysts fail to materialize. Short-term momentum is accelerating sharply, with the stock gaining 22.6% in the past month and 11.6% over the past three months, compared to the S&P 500's -1.25% and 13.56% returns, respectively. The one-month relative strength of 23.86% versus the market underscores a powerful near-term rally that has diverged from the broader market's recent weakness, potentially signaling a flight to defensive healthcare names. However, the three-month relative strength is slightly negative at -1.93%, suggesting the longer-term trend may be more measured. Key technical support lies at the 52-week low of $137.75, while resistance is at the 52-week high of $240.93. A breakout above $240.93 would signal a continuation of the uptrend and likely attract further buying, while a breakdown below recent support near $220 could indicate a correction. With a beta of 0.49, Cardinal Health is significantly less volatile than the market, making it a lower-risk holding that may appeal to conservative investors.

Revenue growth has been robust, with the most recent quarter (Q2 FY2026, ending Dec 2025) reporting $65.44 billion, up 18.4% year-over-year from $55.26 billion in the prior-year quarter. This marks an acceleration from the 9.1% growth seen in Q1 FY2026 and the 9.6% growth in Q4 FY2025, driven by strong performance in the Pharmaceutical segment ($60.67 billion in the quarter) and contributions from acquisitions. The multi-quarter trend shows revenue growth re-accelerating after a period of moderation, supported by increased pharmaceutical demand and specialty drug volumes. Profitability remains thin but improving, with net income of $471 million in Q2 FY2026, up from $400 million a year ago, and gross margin of 3.38%, slightly below the 3.51% in the prior-year quarter. Operating margin was 1.08%, up from 0.99% in Q2 FY2025, reflecting better cost control and operating leverage. While margins are low, this is typical for the pharmaceutical distribution industry, where high volumes compensate for razor-thin margins. The company is profitable, with a trailing net margin of 0.70%, and the trajectory shows gradual expansion. The balance sheet is a concern due to negative equity, with a debt-to-equity ratio of -3.36, stemming from share buybacks and accumulated deficits. However, free cash flow generation is strong, with TTM free cash flow of $5.51 billion, providing ample liquidity for debt service and investments. The current ratio of 0.94 indicates slightly tight short-term liquidity, but operating cash flow of $686 million in Q2 FY2026 covers capital expenditures of $131 million comfortably.